CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone, muscle, red blood cells and vasculature, today announced that it will present results from preclinical studies of its anti-angiogenesis program, ACE-041, at the American Association for Cancer Research (AACR) 100th Annual Meeting 2009 in Denver, Colorado, April 18-22, 2009.
